Salud financiera de hoja de balance de Oramed Pharmaceuticals
Salud financiera controles de criterios 3/6
Oramed Pharmaceuticals tiene un patrimonio de los accionistas total de $162.9M y una deuda total de $51.0M, lo que sitúa su ratio deuda-patrimonio en 31.3%. Sus activos y pasivos totales son $220.6M y $57.7M respectivamente.
Información clave
19.3%
Ratio deuda-patrimonio
US$32.03m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$176.59m |
| Patrimonio | US$165.72m |
| Total pasivo | US$37.93m |
| Activos totales | US$203.65m |
Actualizaciones recientes sobre salud financiera
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Aug 24
Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
May 03Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Dec 22Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?
Jun 12Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Feb 23Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Nov 02Recent updates
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Aug 24Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
May 03Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Dec 22Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality
Sep 21Oramed to hand Korean rights for insulin capsule
Sep 09Oramed to report early-stage trial data for oral COVID-19 shot in 3Q
Jul 07Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?
Jun 12Oramed And Oral Insulin: Can This Small Company Really Do It?
Apr 14Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Feb 23Oramed And The Hurdles Of Developing Oral Insulin
Dec 23Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Nov 02Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress
Oct 04We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation
Aug 24Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
Jul 21Oramed reaches 50% enrollment in late-stage oral insulin study
Jun 08Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
Apr 06The Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Is Up 110% And Shareholders Are Boasting About It
Feb 12
Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($162.6M) de ORMP superan a sus pasivos a corto plazo ($53.2M).
Pasivo a largo plazo: Los activos a corto plazo de ORMP ($162.6M) superan a sus pasivos a largo plazo ($4.4M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: ORMP tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de ORMP ha crecido de 0% a 31.3% en los últimos 5 años.
Cobertura de la deuda: El flujo de caja operativo de ORMP es negativo, por lo que la deuda no está bien cubierta.
Cobertura de intereses: Datos insuficientes para determinar si los pagos de intereses de ORMP sobre su deuda están bien cubiertos por el EBIT.